Mary Jane Helenek is the President and CEO of Luitpold Pharmaceuticals Inc. The company operates three main marketing divisions including American Regent, marketing branded and generic injectable products to US hospitals and surgi-centers and the leading IV iron preparation, Venofer®, to nephrologists and dialysis centers; Animal Health, marketing Adequan®, the leading treatment for lameness in race horses and the only disease modifying osteoarthritic agent on the market; and Osteohealth, which has the leading market share in the bone grafting and regeneration markets with Bio-Oss® and Bio-Gide®. The Division just launched GEM 21S®, the first recombinant growth factor to treat periodontal defects.
Helenek is responsible for all aspects of the business including full P&L responsibility, research & development, clinical trial programs, manufacturing, quality control, sales, marketing and regulatory affairs. She holds several U.S. and international patents dealing with iron carbohydrate complexes.
Prior to joining Luitpold Pharmaceuticals, she was a Hospital Clinical Pharmacist, worked in institutional long-term care and worked as a pharmacist in both independent and chain retail stores throughout Long Island. She is a member of numerous professional associations and organizations including the American Society of Health System Pharmacists, American Society of Nephrology, Kidney Care Partners, and is involved in many humanitarian efforts. Luitpold Pharmaceuticals has donated nearly $2 million to the Red Cross in the last few years for local and worldwide tragedies.
Helenek received her Bachelors degree in Pharmacy, cum laude, her Master's degree in Institutional Pharmacy Administration and a Master's of Business Administration from St John's University.